Orexigen Therapeutics Inc. (NASDAQ:OREX) has adjusted some weight-loss data of its experimental obesity pill Contrave reported previously, and though it plans to amend its recently filed approval application, the move is not expected to affect the drug’s review timeline. Orexigen Therapeutics, Inc. (NASDAQ:OREX) weekly performance is 6.53%. On last trading day company shares ended up $5.71. Analysts mean target price for the company is $11.63. Orexigen Therapeutics, Inc. (NASDAQ:OREX) distance from 50-day simple moving average (SMA50) is -3.70%.
Eisai Co. Ltd. (ADR) (OTCMKTS:ESALY) has exercised its option to jointly develop and commercialize its clinical candidates for Alzheimer’s disease with US biotechnology firm Biogen Idec. The option was included as part of Eisai’s collaboration agreement with Biogen Idec announced in March 2014. Based on the agreement, Eisai and Biogen Idec will co-develop Eisai’s investigational next generation Alzheimer’s disease treatment candidates E2609 and BAN2401 for major markets such as the United States, the European Union and Japan. Eisai Co., Ltd (ADR) (OTCMKTS:ESALY) shares advanced 0.56% in last trading session and ended the day on $41.08.
AbbVie Inc (NYSE:ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including patients with cirrhosis. The NDS is supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date,1 with six Phase III studies that included more than 2,300 patients in over 25 countries. AbbVie Inc (NYSE:ABBV) shares moved up 0.60% in last trading session and was closed at $53.95, while trading in range of $53.83 -$54.38. AbbVie Inc (NYSE:ABBV) year to date (YTD) performance is 3.89%.
Epizyme Inc (NASDAQ:EPZM) EVP Robert A. Copeland unloaded 5,000 shares of Epizyme stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $22.28, for a total transaction of $111,400.00. Following the transaction, the executive vice president now directly owns 17,561 shares of the company’s stock, valued at approximately $391,259. Epizyme Inc (NASDAQ:EPZM) ended the last trading day at $23.03. Company weekly volatility is calculated as 4.76% and price to cash ratio as 3.22. Epizyme Inc (NASDAQ:EPZM) showed a positive weekly performance of 1.23%.
Shares of Celgene Corporation (NASDAQ:CELG) gained slightly following the announcement of a series of organizational changes to expand its leadership team. The changes are aimed to improve operational efficiencies. Celgene Corporation (NASDAQ:CELG) net profit margin is 19.90% and weekly performance is 1.91%. On last trading day company shares ended up $150.13. Analysts mean target price for the company is $191.67. Celgene Corporation (NASDAQ:CELG) distance from 50-day simple moving average (SMA50) is 3.30%.
Leave a Reply